DENVER, CO — June 3, 2002 —
A short-term treatment to prevent RSV infection in premature infants with lung disease provided significant respiratory and immunologic benefits up to 10 years later, according to researchers at National Jewish Medical and Research Center, the University of Colorado Health Sciences Center and The Children’s Hospital in Denver.
The findings, published in the June issue of The American Journal of Medicine, lend support to the hypothesis that respiratory syncytial virus (RSV) can contribute to the development of asthma. “Preventing these premature infants from contracting an RSV infection during their first winter had long-term benefits for their health,” said Sally Wenzel, M.D., co-author and Professor of Medicine at National Jewish.
“They have better lung function, and fewer colds, asthma attacks and allergies. “The children in the study were infants born 10 to 11 weeks prematurely, who spent weeks in intensive care and on ventilators. Their compromised lungs made them especially susceptible to infection with RSV, a common childhood illness.
In healthy children, RSV usually develops into a relatively harmless upper respiratory infection. But in vulnerable children, such as these premature infants, the RSV infection is more likely to become a serious infection of the lungs. Thirteen of the children in the current study received monthly injections during their first winter of an immune globulin preparation with antibodies to RSV. The short-term trial showed that the preparation was effective at preventing RSV infection.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!